共 50 条
- [41] Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trialCancer Immunology, Immunotherapy, 2020, 69 : 1663 - 1672Amir KhammariJean-Michel NguyenMarie-Thérèse LecciaBernard GuillotSoraya SaiaghMarie-Christine PandolfinoAnne-Chantal KnolGaëlle QuéreuxAnne ChiffolettauNathalie LabarrièreBrigitte Dréno
- [42] Adjuvant Therapy With Capecitabine Postpones Recurrence of Hepatocellular Carcinoma After Curative Resection: A Randomized Controlled TrialANNALS OF SURGICAL ONCOLOGY, 2010, 17 (12) : 3137 - 3144Xia, YongQiu, YingheLi, JunShi, LehuaWang, KuiXi, TaoShen, FengYan, ZhenlinWu, Mengchao
- [43] Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanomaANNALS OF ONCOLOGY, 2023, 34 : S657 - S658Weber, J. S.Haque, W.Markovic, S. N.Salama, A. K. S.Mehmi, I.Sullivan, R. J.Najjar, Y. G.van Akkooi, A. C. J.Menzies, A. M.Long, G. V.Taylor, A. M.Haanen, J. B. A. G.Zijlker, L.Davis, K.Karanth, S.Shah, R.Connolly, L.Norton, D.
- [45] Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinomaCONTROLLED CLINICAL TRIALS, 2003, 24 (02): : 110 - 121Tan, SBChung, YFATai, BCCheung, YBMachin, D
- [46] Phase II randomized, placebo controlled study of sorafenib in combination with dacarbazine in subjects with unresectable Stage III or Stage IV melanomaEJC SUPPLEMENTS, 2007, 5 (04): : 396 - 396McDermott, D.Sosman, J. A.Hodi, F. S.Gonzalez, R.Linette, G.Richards, J.Jakub, J. K.Beeram, M.Patel, K.Hersch, E.
- [47] Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trialCANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (08) : 1663 - 1672Khammari, AmirNguyen, Jean-MichelLeccia, Marie-ThereseGuillot, BernardSaiagh, SorayaPandolfino, Marie-ChristineKnol, Anne-ChantalQuereux, GaelleChiffolettau, AnneLabarriere, NathalieDreno, Brigitte
- [48] Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage III and IV ovarian cancer after interval cytoreductive surgery (FOCUS)JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Lim, Myong CheolKim, Ji HyunPark, BoramLee, Jung-YunChang, Suk-JoonLee, Yoo-YoungChoi, Chel HunPark, Jeong-YeolKim, Dae-YeonHong, Dae GyCho, Hyun-WoongSong, Jae-YunKim, Yun HwanKim, Ki HyungPark, Sang-YoonPark, Sang-YoonJeon, Seob
- [49] Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 TrialANNALS OF SURGICAL ONCOLOGY, 2025, 32 (04) : 2756 - 2764Yoon, Charles H.Ross, Merrick I.Gastman, Brian R.Luke, Jason J.Ascierto, Paolo A.Long, Georgina V.Rutkowski, PiotrKhattak, MuhammadDel Vecchio, Michelede la Cruz Merino, LuisMackiewicz, JacekChiarion-Sileni, VannaSchadendorf, DirkCarlino, Matteo S.Zhao, YujieFukunaga-Kalabis, MizuhoKrepler, ClemensEggermont, Alexander M. M.Gershenwald, Jeffrey E.Sondak, Vernon K.
- [50] Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Cebon, Jonathan S.McArthur, Grant A.Chen, WeisanDavis, Ian D.Gore, Martin EricThompson, John F.Millward, MichaelFindlay, Michael P. N.Dunbar, RodOttensmeier, Christian H. H.Venhaus, Ralph RudolphNathan, Paul D.Dalgleish, Angus GeorgeCerundolo, VincenzoMaraskovsky, EugeneHopkins, WendieMarsden, JeremySmithers, B. MarkHersey, PeterEvans, T. R. Jeffry